Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 6/20 | 0.34 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24827913 | 0.82 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 | |
| SCHEMBL24827889 | 0.82 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 | |
| SCHEMBL24827960 | 0.82 | OGA (0.40) | OGAPANK3 | |
| SCHEMBL26815219 | 0.78 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 | |
| SCHEMBL17404868 | 0.75 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 | |
| SCHEMBL16131123 | 0.74 | POLB (0.42) | TSHRALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL26846118 | 0.74 | OGA (0.39) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL26844919 | 0.74 | ACACB (0.36) | CYP3A4CYP2D6TSHRMEN1KMT2A | |
| SCHEMBL13131096 | 0.73 | USP2 (0.40) | CYP3A4CYP2D6TSHRHSD17B10MEN1 | |
| SCHEMBL11947825 | 0.73 | CYP3A4 (0.53) | CYP3A4CYP2D6TSHRHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542266-B1 | Substituted piperidines as BTK inhibitors | BTK, BLK, SYK | CYP3A4 4146/4885CYP2D6 3342/4885TSHR 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.